ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Oral Abstract Session

Diabetic Kidney Disease: From Mechanisms to Treatment

October 24, 2020 | 05:00 PM - 07:00 PM

Location: Simulive

Session Description

Oral Abstract Session

Learning Pathway(s)

  • Diabetes and Metabolism

Moderators

  • Alessia Fornoni, MD, PhD, FASN
  • Monika A. Niewczas, MD, PhD, MPH

Presentations

  • p53/MicroRNA-214/ULK1 Axis Impairs Renal Tubular Autophagy in Diabetic Kidney Disease
    05:00 PM - 07:00 PM
    Zhengwei Ma, PhD
  • Podocytes-Derived Extracellular Vesicles Mediate Renal Proximal Tubule Cells Dedifferentiation via MicroRNA 221 in Diabetic Nephropathy
    05:00 PM - 07:00 PM
    Hong Su 
  • Whole-Genome Sequencing Identifies a Dominant Negative ADIPOQ Mutation in a Type 2 Diabetic Family Enriched for ESRD
    05:00 PM - 07:00 PM
    Marcus G. Pezzolesi, PhD, MPH
  • Enhancing Kidney DDAH-1 Expression by Adenovirus Delivery Reduces Asymmetric Dimethylarginine and Ameliorates Diabetic Nephropathy
    05:00 PM - 07:00 PM
    Michael Wetzel, PhD 
  • Cell Type Specificity of Hypoxia Signaling in Early Diabetic Kidney Disease (DKD)
    05:00 PM - 07:00 PM
    Jennifer A. Schaub, MD
  • Loss of Functional SCO2 Attenuates Diabetic Kidney Disease in db/db Mice
    05:00 PM - 07:00 PM
    Nehaben A. Gujarati, PhD 
  • Reversal of Diabetic Nephropathy After 10 Years of Pancreas Transplantation Occurs Despite Parallel Podocyte Loss
    05:00 PM - 07:00 PM
    Behzad Najafian, MD 
  • Urinary Proteomics Identifies Proteins Associated with Rapid eGFR Decline in Type 1 Diabetes
    05:00 PM - 07:00 PM
    Christine P. Limonte, MD 
  • Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6
    05:00 PM - 07:00 PM
    Katherine R. Tuttle, MD, FASN 
  • Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes
    05:00 PM - 07:00 PM
    Rajiv Agarwal, MD, MS, FASN